Recent developments include a strategic leadership change with the appointment of a new CFO, a significant licensing and acquisition agreement with Celularity for biomaterial products, and continued revenue growth highlighted in prior quarters.

• NEXGEL announced the appointment of a new CFO amid strategic growth initiatives in April 2026 [N1].
• In March 2026, NEXGEL signed an agreement with Celularity to license and acquire six biomaterial products, involving a $15 million upfront payment and potential milestone payments totaling $20 million, subject to financing conditions [N3].
• The company reported record revenue growth in 2024 with 181% growth in Q4 and 112% for the full year, and a revenue forecast of $13 million for 2025 [N8].
• NEXGEL's revenue doubled in fiscal Q2 2025, indicating strong growth momentum [N5].
• The company expanded its partnership with STADA Arzneimittel AG to launch new health solutions in mid-2025 [N6].

NEXGEL's proprietary manufacturing technology and significant unused production capacity provide a foundation for scaling its contract manufacturing and consumer product businesses. The company's diversified product lines, including branded consumer products and custom/white label offerings, offer multiple revenue streams. Strategic partnerships and licensing agreements, such as the recent deal with Celularity to acquire biomaterial products, could enhance its product portfolio and market reach. The appointment of a new CFO amid strategic growth initiatives may strengthen financial and operational management. The company's focus on gentle, skin-friendly hydrogels and development of medical devices with potential licensing opportunities could open new markets [N3][N1][S1].

NEXGEL operates in a highly competitive industry with larger, well-established competitors possessing greater resources, brand recognition, and distribution channels, which may limit market penetration. The company's reliance on a limited number of sole suppliers for key raw materials exposes it to supply chain disruptions that could adversely affect production and revenue. Sales are made on a purchase order basis without long-term contracts, leading to potential revenue volatility. The company reported net losses and has material weaknesses in internal financial controls, which may impact operational effectiveness and investor confidence. Regulatory approvals for medical devices under development are uncertain, and the company does not intend to commercialize these devices directly, relying instead on partnerships that may not materialize [S1].

NEXGEL's competitive advantages include proprietary electron beam cross-linking manufacturing technology enabling production of hydrogels with precise physical characteristics and gentler skin compatibility due to absence of chemical cross-linking agents. The company operates one of only two facilities capable of producing state-of-the-art hydrogel transdermal products, creating a high barrier to entry. Its diversified product portfolio spans contract manufacturing, branded consumer products, and custom/white label offerings, supported by a multi-channel distribution strategy. The joint venture for converting and packaging expands finished goods delivery capabilities. However, competition from larger, more established companies with greater resources and brand recognition in consumer products and medical devices remains significant. Dependence on sole suppliers for key raw materials and the absence of long-term customer contracts present operational risks [S1].

• Supply Chain Dependence: NEXGEL relies on sole suppliers for certain key raw materials, and interruptions or delays from these suppliers could disrupt production and adversely impact revenue.
• Revenue Volatility: Sales are made on a purchase order basis without long-term contracts, resulting in potential variability and unpredictability in revenue streams.
• Financial Control Weaknesses: The company has identified material weaknesses in internal control over financial reporting, including segregation of duties and review processes, which could affect financial accuracy and compliance.
• Competitive Pressure: NEXGEL faces competition from larger, established companies with greater resources, brand recognition, and distribution capabilities, which may limit its market share growth.
• Regulatory and Commercialization Risks: Medical devices under development require FDA approval and successful licensing or partnership arrangements for commercialization, which are uncertain and may not be achieved.

• NEXGEL, INC. manufactures high water content, electron beam cross-linked aqueous polymer hydrogels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics as a contract manufacturer supplying gels to third parties who incorporate them into their own products [S1].
• The company also markets branded consumer products under multiple brands including MedaGel (SilverSeal, Hexagels, Turfguard), Kenkoderm, and Silly George, distributed via e-commerce, retail partnerships, and medical office channels [S1].
• NEXGEL offers custom and white label hydrogel products, allowing customers to create finished products for branding and resale, with customers paying development fees to mitigate company risk [S1].
• The company is developing medical devices such as NEXDrape (an incise surgical drape) and NEXDerm (an adhesive tape for securing medical lines), intending to license or partner for commercialization rather than direct sales [S1].
• Manufacturing is conducted at a 13,500 square foot facility operating at 15-20% capacity, with significant unused capacity allowing for rapid expansion; the company also has a 50% interest in a joint venture CG Converting and Packaging, LLC, expanding finished goods delivery capabilities [S1].
• NEXGEL is one of two manufacturers using electron beam technology for hydrogels in wound care, cosmetic, and drug delivery industries; the other does not compete in the consumer market [S1].
• The company faces competition in consumer products and medical devices from large established companies such as Johnson & Johnson, Pfizer Consumer Healthcare, and Procter & Gamble, which have greater resources and market presence [S1].
• Raw materials are generally available from multiple sources, but some components are sourced from sole suppliers (Berry Global, DeWolf Chemical, Univar); supply interruptions could adversely impact production and revenue [S1].
• No single customer accounted for 10% or more of revenue in 2024 or 2025, and sales are made on a purchase order basis without long-term contracts, leading to potential variability in orders [S1].
• NEXGEL reported a net loss of $3 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$0.38 per share [S1].
• As of September 30, 2025, the company had $938,000 in cash and cash equivalents; as of December 31, 2025, current assets were $4.338 million and current liabilities $2.956 million, yielding a current ratio of 1.47 and a cash ratio of 0.52 [S1].
• The company has material weaknesses in internal control over financial reporting related to segregation of duties and review of journal entries [S1].
• NEXGEL entered into a material definitive agreement with Celularity, Inc. in March 2026 to license and acquire six biomaterial products, with consideration including a $15 million upfront payment and up to $20 million in milestone payments, subject to financing conditions [N3][S1].
• The company announced a new CFO in April 2026 amid strategic growth initiatives [N1].
• Recent news highlights include record revenue growth in 2024 (181% Q4 growth, 112% full year growth) and a revenue forecast of $13 million for 2025, as well as a 100% revenue increase in fiscal Q2 2025 [N5][N8][N7][N6].